Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20-243 CrossMab

mAbs

Volumn 6, Issue 3, 2014, Pages 739-747

  Zhao, Lei ^a,b,c   Xie, Feiyue ^b   Tong, Xin ^a,b,d   Li, Huafei ^a   Chen, Yaling ^a   Qian, Weizhu ^a   Duan, Shuyan ^d   Zheng, Juan ^d   Zhao, Ziye ^d   Li, Bohua ^a   Zhang, Dapeng ^a,c   Zhao, Jian ^a,b,c   Dai, Jianxin ^a,b,c,d   Wang, Hao ^a,b,c,d   Hou, Sheng ^a,b,c,d   Guo, Yajun ^a,b,c,d  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c Shanghai Key Laboratory of Veterinary Science   (China)

^d LIAOCHENG UNIVERSITY   (China)

Author keywords

CD20 antibody; CrossMab; HLA DR; Lysosome mediated cell death; Resistant cancer cell; Rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; CD20 243 CROSSMAB; CD20 ANTIBODY; HLA DR ANTIGEN; RITUXIMAB; UNCLASSIFIED DRUG; CD20 ANTIGEN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DAUDI CELL LINE; DRUG CYTOTOXICITY; DRUG EFFICACY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LYSOSOME; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RAJI CELL LINE; ANIMAL; DRUG SCREENING; HUMAN; IMMUNOLOGY; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; CELL LINE, TUMOR; FEMALE; HLA-DR ANTIGENS; HUMANS; IMMUNOGLOBULIN G; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; LYSOSOMES; MICE; MICE, SCID; RITUXIMAB; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899717758     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.28613     Document Type: Article

References (45)

1. Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet 2012; 380:848-57; PMID:22835603; http://dx.doi.org/10.1016/S0140-6736(12)60605-9
2. Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin lymphoma: an update. Lancet Oncol 2004; 5:341-53; PMID:15172354; http://dx.doi.org/10.1016/S1470- 2045(04)01490-1
3. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007; 44:3823-37; PMID:17768100; http://dx.doi.org/10.1016/j.molimm.2007.06.151
4. Calcagno A, Rostagno R, Di Perri G. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 2012; 367:877-8; PMID:22931340
5. Oflazoglu E, Audoly LP. Evolution of anti-CD20 monoclonal antibody therapeutics in oncology. MAbs 2010; 2:14-9; PMID:20081379; http://dx.doi.org/ 10.4161/mabs.2.1.10789
6. Lim SH, Beers SA, French RR, Johnson PWM, Glennie MJ, Cragg MS. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 2010; 95:135-43; PMID:19773256; http://dx.doi.org/10.3324/haematol.2008.001628
7. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104:2635-42; PMID:15226177; http://dx.doi.org/10.1182/blood-2004-03-1110
8. Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan CHT, Tutt A, Beers SA, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011; 117:4519-29; PMID:21378274; http://dx.doi.org/10.1182/blood-2010-07-296913
9. Niederfellner G, Lammens A, Mundigl O, Georges GJ, Schaefer W, Schwaiger M, Franke A, Wiechmann K, Jenewein S, Slootstra JW, et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood 2011; 118:358-67; PMID:21444918; http://dx.doi.org/10.1182/blood-2010-09-305847
10. Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115:4393-402; PMID:20194898; http://dx.doi.org/10. 1182/blood-2009-06-225979
11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
12. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70; PMID:10647931; http://dx.doi.org/10.1016/S0092-8674(00)81683-9
13. Kontermann R. Dual targeting strategies with bispecific antibodies. MAbs 2012; 4; (Forthcoming); PMID:22453100; http://dx.doi.org/10.4161/mabs.4.2.19000
14. Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, McCarthy D, Zhu R-RR, Santora L, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007; 25:1290-7; PMID:17934452; http://dx.doi.org/10.1038/nbt1345
15. Gupta P, Goldenberg DM, Rossi EA, Cardillo TM, Byrd JC, Muthusamy N, Furman RR, Chang C-H. Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. Blood 2012; 119:3767-78; PMID:22271448; http://dx.doi.org/10.1182/ blood-2011-09-381988
16. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002; 53:615-27; PMID:11818492; http://dx.doi.org/10.1146/annurev.med.53.082901.103929
17. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2:48-58; PMID:11902585; http://dx.doi.org/10.1038/nrc706
18. Puissant A, Dufies M, Raynaud S, Cassuto J-P, Auberger P. Targeting lysosomes to eradicate imatinib-resistant chronic myelogenous leukemia cells. Leukemia 2010; 24:1099-101; PMID:20376083; http://dx.doi.org/10.1038/leu.2010.55
19. Fehrenbacher N, Jäättelä M. Lysosomes as targets for cancer therapy. Cancer Res 2005; 65:2993-5; PMID:15833821
20. Ivanov A, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL, Potter KN, Murray S, Chan CHT, Klymenko T, et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 2009; 119:2143-59; PMID:19620786
21. Dechant M, Bruenke J, Valerius T. HLA class II antibodies in the treatment of hematologic malignancies. Semin Oncol 2003; 30:465-75; PMID:12939715; http://dx.doi.org/10.1016/S0093-7754(03)00252-5
22. Broxmeyer HE, Juliano L, Lu L, Platzer E, Dupont B. HLA-DR human histocompatibility leukocyte antigens-restricted lymphocyte-monocyte interactions in the release from monocytes of acidic isoferritins that suppress hematopoietic progenitor cells. J Clin Invest 1984; 73:939-53; PMID:6231314; http://dx.doi.org/10.1172/JCI111318
23. Stein R, Qu Z, Chen S, Solis D, Hansen HJ, Goldenberg DM. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab. Blood 2006; 108:2736-44; PMID:16778139; http://dx.doi.org/10.1182/blood-2006-04-017921
24. Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science 2013; 341:1192-8; PMID:24031011; http://dx.doi.org/10.1126/science.1241145
25. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006; 6:343-57; PMID:16622479; http://dx.doi.org/10.1038/nri1837
26. Schaefer W, Regula JTJ, Bähner M, Schanzer J, Croasdale R, Dürr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 2011; 108:11187-92; PMID:21690412; http://dx.doi.org/10.1073/pnas.1019002108
27. Atwell S, Ridgway JBJ, Wells JAJ, Carter P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol 1997; 270:26-35; PMID:9231898; http://dx.doi.org/10.1006/jmbi.1997.1116
28. Ridgway JB, Presta LG, Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996; 9:617-21; PMID:8844834; http://dx.doi.org/10.1093/protein/9.7.617
29. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83:435-45; PMID:7506951
30. Bezombes C, Grazide S, Garret C, Fabre C, Quillet-Mary A, Müller S, Jaffrézou J-P, Laurent G. Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood 2004; 104:1166-73; PMID:15126316; http://dx.doi.org/10.1182/ blood-2004-01-0277
31. Li B, Zhao L, Guo H, Wang C, Zhang X, Wu L, Chen L, Tong Q, Qian W, Wang H, et al. Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma. Blood 2009; 114:5007-15; PMID:19828699; http://dx.doi.org/10.1182/blood-2009-06-225474
32. Bland JM, Altman DG. Survival probabilities (the Kaplan-Meier method). BMJ 1998; 317:1572; PMID:9836663; http://dx.doi.org/10.1136/bmj.317.7172.1572
33. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012; 12:278-87; PMID:22437872; http://dx.doi.org/10.1038/nrc3236
34. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001; 1:118-29; PMID:11905803; http://dx.doi.org/10.1038/35101072
35. Alinari L, Yu B, Christian BA, Yan F, Shin J, Lapalombella R, Hertlein E, Lustberg ME, Quinion C, Zhang X, et al. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood 2011; 117:4530-41; PMID:21228331; http://dx.doi.org/10.1182/blood-2010-08-303354
36. Rossi EA, Rossi DL, Stein R, Goldenberg DM, Chang C-H. A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells. Cancer Res 2010; 70:7600-9; PMID:20876805; http://dx.doi.org/10.1158/0008-5472.CAN-10-2126
37. Petersen NHT, Olsen OD, Groth-Pedersen L, Ellegaard A-M, Bilgin M, Redmer S, Ostenfeld MS, Ulanet D, Dovmark TH, Lønborg A, et al. Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. Cancer Cell 2013; 24:379-93; PMID:24029234; http://dx.doi.org/10.1016/j.ccr.2013.08.003
38. Groth-Pedersen L, Jäättelä M. Combating apoptosis and multidrug resistant cancers by targeting lysosomes. Cancer Lett 2013; 332:265-74; PMID:20598437; http://dx.doi.org/10.1016/j.canlet.2010.05.021
39. Stein R, Gupta P, Chen X, Cardillo TM, Furman RR, Chen S, Chang C-H, Goldenberg DM. Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways. Blood 2010; 115:5180-90; PMID:20101022; http://dx.doi.org/10.1182/blood-2009-06-228288
40. Gingrich RD, Dahle CE, Hoskins KF, Senneff MJ. Identification and characterization of a new surface membrane antigen found predominantly on malignant B lymphocytes. Blood 1990; 75:2375-87; PMID:1693529
41. Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H, Knight J, Starostik P, Deans J, Hernandez-Ilizaliturri FJ. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res 2008; 14:1561-70; PMID:18316581; http://dx.doi.org/10.1158/1078-0432.CCR-07-1254
42. Jazirehi AR, Vega MI, Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 2007; 67:1270-81; PMID:17283164; http://dx.doi.org/10. 1158/0008-5472.CAN-06-2184
43. Carter P. Bispecific human IgG by design. J Immunol Methods 2001; 248:7-15; PMID:11223065; http://dx.doi.org/10.1016/S0022-1759(00)00339-2
44. Cragg MS, Morgan SM, Chan HTC, Morgan BP, Filatov AV, Johnson PWM, French RR, Glennie MJ. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003; 101:1045-52; PMID:12393541; http://dx.doi.org/10.1182/blood-2002-06-1761
45. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998; 91:1644-52; PMID:9473230